HAVN Life Sciences Inc.
HAVLF
$0.001
$0.000.00%
OTC PK
| 01/31/2023 | 10/31/2022 | ||||
|---|---|---|---|---|---|
| Revenue | -103.76% | 347.92% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -103.76% | 347.92% | |||
| Cost of Revenue | -37.62% | 137.54% | |||
| Gross Profit | -140.74% | 787.13% | |||
| SG&A Expenses | -21.28% | -28.34% | |||
| Depreciation & Amortization | 0.00% | -99.42% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -31.75% | -17.05% | |||
| Operating Income | -5.80% | 41.78% | |||
| Income Before Tax | 72.45% | -104.06% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 72.45% | -104.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 72.45% | -104.06% | |||
| EBIT | -5.80% | 41.78% | |||
| EBITDA | -5.80% | 40.49% | |||
| EPS Basic | 82.78% | -84.03% | |||
| Normalized Basic EPS | 36.73% | 44.32% | |||
| EPS Diluted | 82.86% | -84.93% | |||
| Normalized Diluted EPS | 36.73% | 44.32% | |||
| Average Basic Shares Outstanding | 59.91% | 10.87% | |||
| Average Diluted Shares Outstanding | 59.91% | 10.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||